En español
NIDA

Study identifies a brain pathway involved in drug relapse after cessation of contingency management

Science Spotlight

October 11, 2017

Painting of rat looking at sign that has relapse pointing one way and recovery pointing in the opposite directionCourtesy of Marco Venniro

A team of researchers at the National Institute on Drug Abuse (NIDA) has identified what may be the crucial brain circuit involved in relapse to drug use when an effective behavioral treatment for drug addiction, known as contingency management, is discontinued. Contingency management uses non-drug rewards, such as cash stipends, prizes, or coupons for retail goods, to encourage people to remain drug-free. Most patients, however, will relapse when they no longer receive the alternative reward.

Researchers used an animal model, where rats voluntarily abstain from drug self-administration when given food rewards. In this model, the rats choose to abstain from methamphetamine or heroin when an alternative non-drug reward is available, but relapse to drug seeking when the alternative reward is removed. Using chemogenetic manipulations, electron microscopy, and other techniques, the scientists identified the anterior insular cortex-to-central amygdala nerve path as critical to the relapse process.

These findings provide insights into the brain mechanisms underlying relapse after successful contingency management treatment and identify a potential novel target for relapse prevention using brain stimulation methods.

The research was performed by Marco Venniro and other members of the laboratories of Yavin Shaham and Marisela Morales at the NIDA Intramural Research Program, in collaboration with other NIDA investigators, and extramural investigators.

For a copy of the paper, go to “The anterior insular cortex→central amygdala glutamatergic pathway is critical to relapse after contingency management,” published in Neuron.

For more information about drug addiction treatment, go to: https://www.drugabuse.gov/publications/drugfacts/treatment-approaches-drug-addiction

For more information, contact the NIDA press office at media@nida.nih.gov or 301-443-6245. Follow NIDA on Twitter and Facebook.

Contact:
NIDA Press Office
301-443-6245
media@nida.nih.gov

About the National Institute on Drug Abuse (NIDA): The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. Fact sheets on the health effects of drugs and information on NIDA research and other activities can be found at www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or email requests to drugpubs@nida.nih.gov. Online ordering is available at drugpubs.drugabuse.gov. NIDA’s media guide can be found at www.drugabuse.gov/publications/media-guide/dear-journalist, and its easy-to-read website can be found at www.easyread.drugabuse.gov. You can follow NIDA on Twitter and Facebook.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH. . .Turning Discovery Into Health®

News Releases

2017

2016

2015

2014

2013

2012

2011

2010

Get this Publication

    Cite this article

    NIDA. (2017, October 11). Study identifies a brain pathway involved in drug relapse after cessation of contingency management. Retrieved from https://www.drugabuse.gov/news-events/news-releases/2017/10/study-identifies-brain-pathway-involved-in-drug-relapse-after-cessation-contingency-management

    press ctrl+c to copy
    Receive Latest Science Articles in your Email!
    You will only receive messages related to Latest Science